In this poster we focus on:
- Development of robust feeder-free 3D differentiation protocol to reduce iNK cells
- Transnational validation of iNK functionality with freshly isolated CLL patient tumor cells
- Enhances CLL patient tumor cell killing with CAR19 iNK
- EVOcells Oncology programs
1 Evotec, Toulouse, France
2 Evotec, Gottingen, Germany
3 Evotec, Munich, Germany
4 Oncopole (IUCT-O), Toulouse, France
5 ME and AH contributed equally to the work
